Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy

Journal of the American Academy of Dermatology

Volumn 59, Issue 5 SUPPL., 2008, Pages

  Lozzi, Gian Piero ^a   Coletti, Gino ^b   Peris, Ketty ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SKIN LYMPHOMA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; BUTTOCKS; COMBINED MODALITY THERAPY; HUMANS; INJECTIONS, INTRALESIONAL; LYMPHOMA; MALE; MIDDLE AGED; RECURRENCE; SKIN NEOPLASMS; THIGH;

EID: 53349143100     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.04.029     Document Type: Article

References (6)

1. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 26 (2007) 3603-3613
2. Kerl K., Prins C., Saurat J.H., and French L.E. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 155 (2006) 1197-1200
3. Davis T.A., Czerwinski D.K., and Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 5 (1999) 611-615
4. Rawal Y.B., Nuovo G.J., Frambach G.E., Porcu P., Baiocchi R.A., and Magro C.M. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol 32 (2005) 616-621
5. Clarke L.E., Bayerl M.G., Ehmann W.C., and Helm K.F. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. J Cutan Pathol 30 (2003) 459-462
6. Chu P.G., Chen Y.Y., Molina A., Arbert D.A., and Weiss L.M. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma 43 (2002) 2335-2341